Breaking down bone

New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Bone metastases are the most common skeletal complication of malignancy. Tumor cells disrupt normal bone remodeling to promote bone destruction and its associated morbidity. In the August 15, 2009, issue of Genes & Development, Lu and colleagues (pp. 1882-1894) propose a novel molecular mechanism by which tumor-produced metalloproteinases release epidermal growth factor (EGF) ligands to activate the central osteoclastogenic pathway receptor activator of NF-κB ligand (RANKL) to promote breast cancer osteolysis. This work has important therapeutic applications that may quickly translate to more effective treatment for bone metastases.

Original languageEnglish
Pages (from-to)2117-2123
Number of pages7
JournalGenes and Development
Volume23
Issue number18
DOIs
StatePublished - Sep 15 2009

Fingerprint

Osteolysis
Metalloproteases
Breast Neoplasms
Bone and Bones
Neoplasm Metastasis
Ligands
Neoplasms
Bone Remodeling
Epidermal Growth Factor
Morbidity
Genes
Therapeutics

Keywords

  • Bone metastasis
  • Breast cancer
  • EGFR
  • Metalloprotease
  • Osteoclastogenesis

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Breaking down bone : New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. / Guise, Theresa.

In: Genes and Development, Vol. 23, No. 18, 15.09.2009, p. 2117-2123.

Research output: Contribution to journalArticle

@article{93435f38e85f4a68b523efd5a761b842,
title = "Breaking down bone: New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases",
abstract = "Bone metastases are the most common skeletal complication of malignancy. Tumor cells disrupt normal bone remodeling to promote bone destruction and its associated morbidity. In the August 15, 2009, issue of Genes & Development, Lu and colleagues (pp. 1882-1894) propose a novel molecular mechanism by which tumor-produced metalloproteinases release epidermal growth factor (EGF) ligands to activate the central osteoclastogenic pathway receptor activator of NF-κB ligand (RANKL) to promote breast cancer osteolysis. This work has important therapeutic applications that may quickly translate to more effective treatment for bone metastases.",
keywords = "Bone metastasis, Breast cancer, EGFR, Metalloprotease, Osteoclastogenesis",
author = "Theresa Guise",
year = "2009",
month = "9",
day = "15",
doi = "10.1101/gad.1854909",
language = "English",
volume = "23",
pages = "2117--2123",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "18",

}

TY - JOUR

T1 - Breaking down bone

T2 - New insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases

AU - Guise, Theresa

PY - 2009/9/15

Y1 - 2009/9/15

N2 - Bone metastases are the most common skeletal complication of malignancy. Tumor cells disrupt normal bone remodeling to promote bone destruction and its associated morbidity. In the August 15, 2009, issue of Genes & Development, Lu and colleagues (pp. 1882-1894) propose a novel molecular mechanism by which tumor-produced metalloproteinases release epidermal growth factor (EGF) ligands to activate the central osteoclastogenic pathway receptor activator of NF-κB ligand (RANKL) to promote breast cancer osteolysis. This work has important therapeutic applications that may quickly translate to more effective treatment for bone metastases.

AB - Bone metastases are the most common skeletal complication of malignancy. Tumor cells disrupt normal bone remodeling to promote bone destruction and its associated morbidity. In the August 15, 2009, issue of Genes & Development, Lu and colleagues (pp. 1882-1894) propose a novel molecular mechanism by which tumor-produced metalloproteinases release epidermal growth factor (EGF) ligands to activate the central osteoclastogenic pathway receptor activator of NF-κB ligand (RANKL) to promote breast cancer osteolysis. This work has important therapeutic applications that may quickly translate to more effective treatment for bone metastases.

KW - Bone metastasis

KW - Breast cancer

KW - EGFR

KW - Metalloprotease

KW - Osteoclastogenesis

UR - http://www.scopus.com/inward/record.url?scp=70349108389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349108389&partnerID=8YFLogxK

U2 - 10.1101/gad.1854909

DO - 10.1101/gad.1854909

M3 - Article

VL - 23

SP - 2117

EP - 2123

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 18

ER -